ES2183166T3 - Ensayo de cribado por triple hibrido. - Google Patents

Ensayo de cribado por triple hibrido.

Info

Publication number
ES2183166T3
ES2183166T3 ES97921370T ES97921370T ES2183166T3 ES 2183166 T3 ES2183166 T3 ES 2183166T3 ES 97921370 T ES97921370 T ES 97921370T ES 97921370 T ES97921370 T ES 97921370T ES 2183166 T3 ES2183166 T3 ES 2183166T3
Authority
ES
Spain
Prior art keywords
molecula
binding
hybrid
expression
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97921370T
Other languages
English (en)
Inventor
Jun Liu
Edward J Licitra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of ES2183166T3 publication Critical patent/ES2183166T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE PROPORCIONAN UN PROCEDIMIENTO Y KIT PARA IDENTIFICAR Y CARACTERIZAR UN COMPONENTE CELULAR O MOLECULA PEQUEÑA. EL PROCEDIMIENTO Y KIT INCLUYEN UNA MOLECULA HIBRIDA DE LIGANDO (7) FORMADA POR DOS LIGANDOS, DE MANERA QUE UNO DE ELLOS SEA LA MOLECULA PEQUEÑA (7B) CUYA ESPECIFICIDAD SE DESEA DETERMINAR, MIENTRAS QUE EL OTRO LIGANDO TIENE ESPECIFICIDAD PARA UN BLANCO PREDETERMINADO (7A). EL LIGANDO HIBRIDO SE INTRODUCE EN UN ENTORNO QUE CONTIENE: UN PRIMER VECTOR DE EXPRESION QUE CODIFICA UN BLANCO PARA UNO DE LOS LIGANDOS VINCULADOS A UNA SECUENCIA DE CODIFICACION PARA UN PRIMER MODULO TRANSCRIPCIONAL (8); Y UN SEGUNDO VECTOR DE EXPRESION QUE INCLUYE UN BLANCO PARA EL OTRO LIGANDO VINCULADO A UNA SECUENCIA DE CODIFICACION DE UN SEGUNDO MODULO TRANSCRIPCIONAL (9). EL ENTORNO CONTIENE ADEMAS UN TERCER VECTOR (6) QUE INCLUYE UN GEN INFORMADOR, EN EL QUE LA EXPRESION DEL GEN REPORTER (5) DEPENDE DE LA PROXIMIDAD DE LOS MODULOS TRANSCRIPCIONALES PRIMERO Y SEGUNDO, QUE QUEDA FACILITADA POR LA FIJACION DE AMBOS LIGANDOS DE LA MOLECULA HIBRIDA DE LIGANDOS A SUS BLANCOS.
ES97921370T 1996-04-26 1997-04-25 Ensayo de cribado por triple hibrido. Expired - Lifetime ES2183166T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1734196P 1996-04-26 1996-04-26

Publications (1)

Publication Number Publication Date
ES2183166T3 true ES2183166T3 (es) 2003-03-16

Family

ID=21782024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97921370T Expired - Lifetime ES2183166T3 (es) 1996-04-26 1997-04-25 Ensayo de cribado por triple hibrido.

Country Status (8)

Country Link
US (1) US5928868A (es)
EP (1) EP0907750B1 (es)
JP (1) JP2000508923A (es)
AT (1) ATE224454T1 (es)
CA (1) CA2252886C (es)
DE (1) DE69715621T2 (es)
ES (1) ES2183166T3 (es)
WO (1) WO1997041255A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891021B2 (en) * 1993-02-12 2005-05-10 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
US6972193B1 (en) * 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US6841347B1 (en) * 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
US6187535B1 (en) 1998-02-18 2001-02-13 Institut Pasteur Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides
WO1999067639A1 (en) * 1998-06-25 1999-12-29 Caliper Technologies Corporation High throughput methods, systems and apparatus for performing cell based screening assays
CA2338247A1 (en) * 1998-07-28 2000-02-10 Vimal D. Mehta General screening method for ligand-protein interactions
EP2365081A3 (en) 1999-04-12 2012-07-18 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
EP1792989A1 (en) 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
WO2001012811A1 (en) 1999-08-12 2001-02-22 Urogenesys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
DK1220913T3 (da) 1999-10-05 2009-03-16 Agensys Inc G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2001049874A1 (en) * 2000-01-06 2001-07-12 Caliper Technologies Corp. Methods and systems for monitoring intracellular binding reactions
CA2398010A1 (en) * 2000-01-24 2001-07-26 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
US6406863B1 (en) * 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US6410246B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
EP2075582A3 (en) 2000-07-12 2010-01-06 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
CA2420543C (en) 2000-08-22 2013-04-02 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
HRP20010018A2 (en) 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
US20020168737A1 (en) * 2001-01-24 2002-11-14 Cornish Virginia W. Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2002086450A2 (en) * 2001-04-20 2002-10-31 President And Fellows Of Harvard College Compositions and methods for the identification of protein interactions in vertebrate cells
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
AU2002358520A1 (en) * 2001-11-28 2003-06-10 Graffinity Pharmaceuticals Ag Method for the selection and identification of peptide or protein molecules by means of phase display
AU2002352069A1 (en) * 2001-11-28 2003-06-10 Graffinity Pharmaceuticals Ag Surface plasmon resonance (spr) sensor surface support
DE10220602A1 (de) * 2001-11-28 2003-06-26 Graffinity Pharmaceuticals Ag Verfahren zur Selektion und Identifikation von Peptid- oder Proteinmolekülen mittels Phage Display
US20030138785A1 (en) * 2001-12-21 2003-07-24 Stephan Kopytek In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID")
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2003070173A2 (en) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003211113B2 (en) * 2002-02-15 2007-08-09 Merckle Gmbh Antibiotic conjugates
US7083918B2 (en) * 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
RU2330858C2 (ru) * 2002-07-08 2008-08-10 Глаксомитклайн Истраживацки Центар Загреб Д.О.О. Новые соединения, составы и способы лечения воспалительных заболеваний и состояний
US7157433B2 (en) 2002-07-08 2007-01-02 Glaxosmithkline Istrazivacki Centar Zagreb Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules
PL374646A1 (en) 2002-07-08 2005-10-31 Pliva-Istrazivacki Institutt D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
CA2492074A1 (en) * 2002-07-10 2004-01-15 Stratagene Humanized renilla reniformis green fluorescent protein as a scaffold
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
RU2005141341A (ru) 2003-05-30 2006-06-10 Эйдженсис, Инк., Сша (Us) Полинуклеотид, родственный антигену стволовых клеток простаты (psca), и кодируемый им белок (пептид), гибридома и трансгенное животное для продуцирования антител, композиция для лечения, профилактики, диагностики и прогноза течения раковых заболеваний на их основе (варианты), способ определения их присутствия в исследуемом образце, способ генерации иммунного ответа, способ доставки цитотоксического или диагностического агента в клетку, способ ингибирования роста раковых клеток с их использованием
AU2005250370B2 (en) 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
AU2005263551B2 (en) * 2004-07-16 2009-04-09 Novartis Ag Use of a steroid for enhancement of skin permeability
WO2006046694A1 (ja) * 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 誘導可能に発現するエルゴステロール合成酵素を有する酵母を利用した遺伝子のスクリーニング法
PL1858916T4 (pl) 2005-03-15 2015-04-30 Fujirebio Europe N V Warianty wirusa zapalenia wątroby typu b z obniżoną wrażliwością na analogi nukleozydów i ich zastosowanie
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
WO2007012464A1 (en) * 2005-07-26 2007-02-01 Merckle Gmbh Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase
EP1945795B1 (en) * 2005-09-28 2016-08-10 Attagene, Inc. Methods and constructs for analyzing biological activities of biological specimens and determining states of organism
WO2007042771A1 (en) * 2005-10-10 2007-04-19 Astrazeneca Ab Three hybrid screening assay using reverse transfected mammalian cell arrays
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20090162858A1 (en) * 2007-09-18 2009-06-25 Cornish Virginia W Orthogonal chemical inducer of dimerization
CN101131363B (zh) * 2007-09-30 2010-12-01 南京大学 一种基于酵母三杂交的小分子化合物检测方法
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004321A1 (en) * 1989-09-25 1991-04-04 President And Fellows Of Harvard College Receptor for fk-506
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5115098A (en) * 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
US5362629A (en) * 1991-08-05 1994-11-08 President And Fellows Of Harvard College Detection of immunosuppressants
US5498597A (en) * 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
CZ206195A3 (en) * 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
CA2158274C (en) * 1993-03-31 2000-05-30 Dana Merriman Fowlkes Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
HUT73100A (en) * 1993-07-16 1996-06-28 Harvard College Regulated apoptosis
EP0750630A4 (en) * 1994-03-11 1998-01-07 Ariad Pharma Inc METHOD AND MATERIALS FOR IDENTIFYING INHIBITORS OF MOLECULAR INTERACTIONS, WHICH ARE BROUGHT BY THE SH3 DOMAINS
US6001553A (en) * 1994-04-26 1999-12-14 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
US5989808A (en) * 1994-06-14 1999-11-23 American Cyanamid Company Identification of compounds affecting specific interaction of peptide binding pairs
WO1996002561A1 (en) * 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
DE69534300T2 (de) * 1994-08-18 2006-05-18 Ariad Gene Therapeutics, Inc., Cambridge Neues multimerisierendes reagenz
AU3409295A (en) * 1994-08-18 1996-03-14 Ariad Gene Therapeutics, Inc. Regulatable elimination of gene expression, gene product function and engineered host cells
EP0787207B1 (en) * 1994-11-01 2005-10-26 Ariad Gene Therapeutics, Inc. New method for identifying and evaluating biologically active molecules
US5610015A (en) * 1995-03-23 1997-03-11 Wisconsin Alumni Research Foundation System to detect protein-RNA interactions

Also Published As

Publication number Publication date
CA2252886C (en) 2008-02-12
ATE224454T1 (de) 2002-10-15
DE69715621D1 (de) 2002-10-24
DE69715621T2 (de) 2003-05-22
WO1997041255A1 (en) 1997-11-06
EP0907750A1 (en) 1999-04-14
JP2000508923A (ja) 2000-07-18
EP0907750B1 (en) 2002-09-18
CA2252886A1 (en) 1997-11-06
US5928868A (en) 1999-07-27

Similar Documents

Publication Publication Date Title
ES2183166T3 (es) Ensayo de cribado por triple hibrido.
NO986027D0 (no) Forbindelser
AR039768A1 (es) Virus oncoliticos como agentes de determinacion del fenotipo de neoplasmas
ATE251805T1 (de) Verfahren zur herstellung von polybenzimidazol- pasten und -gelen zur verwendung in brennstoffzellen
BR0211396A (pt) Processo para acionar um aplicativo com a ajuda de uma estação móvel
DE59814080D1 (de) Gasdiffusionselektrode mit verringertem diffusionsvermögen für wasser und polymerelektrolytmembran-brennstoffzelle
AR006138A1 (es) Un circuito integrado perfeccionado y el procedimiento de utilizacion de dicho circuito integrado.
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
ES2193604T3 (es) Procedimiento para la coordinacion de componentes de una red.
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
DE60238678D1 (de) Leitungsvermittelte und paketvermittelte kommunikation
ATE254648T1 (de) Rot-emittierende (8,9)benzophenoxazin- nukleinsäurefarbstoffe und verfahren zu deren verwendung
SE9700768D0 (sv) Förfarande för att introducera funktionalitet
FR2448723B1 (es)
DE60202277D1 (de) Regenerative brennstofzelle mit ph-kontrolle
DE69515460D1 (de) Oberflächenmontierter prüfpunkt zum freihändigen prüfen von schaltungen
BR9711776A (pt) Conjunto de contato, processo para sua fabricação, e, pacote de bateria para um dispositivo eletrónico
DE59010347D1 (de) Substituierte N-(Chinolin-2-yl-methoxy)benzylsulfonylharnstoffe
BR9908162A (pt) Grupo de contatos elétricos vedados passìvel de teste
KR910015134A (ko) 무선전화장치
NO891260L (no) Fremgangsmaate for fremstilling av 4-aryl-4-piperidin (eller pyrrolidin eller hexahydroazepin) carbinoler.
DE59705547D1 (de) Gasgenerator, insbesondere für gurtstraffer
ES493536A0 (es) Procedimiento para revestir una caja catodica que tiene una pluralidad de catodos foraminados con cavidad, con un dia- fragma sintetico.
BR9802433A (pt) Tira teste de painel de placa de circuito e processo de montagem associado.
BR0211568A (pt) Processo para suporte de vários algoritmos de soma de teste em um nó de rede